Literature DB >> 2139486

[Animal experiment studies of the toxicity of fluorodeoxyuridine (FUDR) and 5-fluorouracil (FU) within the scope of regional liver infusion chemotherapy].

P Schlag1, J Yi, P Friedl, W Hull, M Berger.   

Abstract

In this study we examined the cytostatic compounds 5 FU and FUDR which are most frequently used in regional chemotherapy for any incidence of hepatobiliary toxicity in animals. For this we compared the intraarterial as well as the intraportal application. Differences between the treatment groups were found in the biliary extraction of these two cytostatic agents. The quantity of metabolites in the bile which could be proven by the MR-spectroscope was highest following intraarterial FUDR infusion, but strong deviations were found in individual cases. A correlation of these findings with the observed frequent hepatobiliary side effects could not be found. It could be shown that the rate and severity of chemical hepatitis and lymphocytic infiltrations in the periportal fields of the liver has no connection to either the cytostatic agent used nor the application form used. Although a sclerosing cholangitis could only be seen in intraarterial therapy. In these cases both cytostatic agents under observation were found to be responsible for this effect in the examined animals. The incidence of sclerosing cholangitis during regional chemotherapy of liver metastases with fluoridised pyrimidines seems to be contingent on multiple factors such as circulation disturbances in combination with drug toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139486     DOI: 10.1007/bf00713391

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  15 in total

1.  Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine.

Authors:  D Hohn; J Melnick; R Stagg; D Altman; M Friedman; R Ignoffo; L Ferrell; B Lewis
Journal:  J Clin Oncol       Date:  1985-01       Impact factor: 44.544

2.  Regional arterial chemotherapy of liver tumours. I. Performance comparison between a totally implantable pump and a conventional access system.

Authors:  D Civalleri; F Cafiero; M Cosimelli; W Craus; R Doci; M Repetto; G Simoni
Journal:  Eur J Surg Oncol       Date:  1986-09       Impact factor: 4.424

3.  [Regional chemotherapy in liver metastases and prognosis].

Authors:  C Hottenrott; M Lorenz; A Encke
Journal:  Lebensversicher Med       Date:  1986-09-01

4.  Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion.

Authors:  D C Hohn; A A Rayner; J S Economou; R J Ignoffo; B J Lewis; R J Stagg
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

5.  [Sclerosing cholangitis after chemotherapy by continuous hepatic intra-arterial infusion of fluorodeoxyuridine].

Authors:  J F Bergmann; P Rougier; C Liguory; E S Zafrani; J M Métreau; D Dhumeaux
Journal:  Gastroenterol Clin Biol       Date:  1986-02

6.  Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation.

Authors:  W J Shea; B E Demas; H I Goldberg; D C Hohn; L D Ferrell; R K Kerlan
Journal:  AJR Am J Roentgenol       Date:  1986-04       Impact factor: 3.959

7.  Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries.

Authors:  M M Kemeny; D Goldberg; J D Beatty; D Blayney; S Browning; J Doroshow; L Ganteaume; R L Hill; W A Kokal; D U Riihimaki
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

8.  A reversible enteropathy complicating continuous hepatic artery infusion chemotherapy with 5-fluoro-2-deoxyuridine.

Authors:  W L Gluck; O E Akwari; F M Kelvin; B J Goodwin
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860

9.  The implanted pump in metastatic colorectal cancer of the liver. Risk versus benefit.

Authors:  L P Johnson; S E Rivkin
Journal:  Am J Surg       Date:  1985-05       Impact factor: 2.565

10.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.